

MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA





CAP RISK SCORING SYSTEM

A risk score (total point score) for a given patient is obtained by summing the patient age in years (age -10 for females) and the points for each applicable patient characteristic. A risk score > 90 is associated with a mortality rate ranging from 8%-29%, therefore hospitalization is recommended.

Patient Characteristic	Points Assigned
Demographic Factors	
Age: male	age (in yrs)
Age: female	age (in yrs)-10
Nursing home resident	+10
Comorbid Illnesses	
Neoplastic disease	+30
Liver disease	+20
Congestive heart failure	+10
Cerebrovascular disease	+10
Renal disease	+10
Physical Examination Findings	
Altered mental status	+20
Respiratory rate \geq 30/minute	+20
Systolic blood pressure < 90 mm Hg	+20
Temperature < 35 degrees C or > 40 degrees C	+15
$Pulse \ge 125/minute$	+10
Pleural effusion	+10
Laboratory Findings	
pH < 7.35	+30
BUN > 10.7 mmol/L	+20
Sodium < 130 mEq/L	+20
Glucose > 13.9 mmol/L	+10
Hematocrit $< 30\%$	+10
$p O_2 < 60 \text{ mm Hg}^{\circ}$	+10

* Oxygen saturation < 90% also considered abnormal.

References:

- Bartlett JG, et al. Practice guidelines for the management of community-acquired pneumonia in adults. *Clinical Infectious Diseases*. 2000;31:347-382.
- Fine MJ, et al. Validation of pneumonia prognosis index using the Medis Group Comparative Hospital Database. Am J Med. 1993;94:153.
- www.Nationalpneumonia.org/Quality_Indicators/Quality_Indicators.html

PNEUMONIA



RECOMMENDED ANTIBIOTICS

FOR EMPIRIC TREATMENT OF CAP

▶ β-lactams:

► Macrolides:

ampicillin-sulbactam cefepime cefotaxime ceftriaxone cefuroxime imipenem-cilastatin meropenem piperacillin-tazobactam azithromycin clarithromycin erythromycin

> Quinolones:

ciprofloxacin gatifloxacin levofloxacin moxifloxacin ofloxacin sparfloxacin trovafloxacin

Non-ICU Patients

- > β-lactam [IV] + macrolide [PO or IV] or
- ➤ Quinolone [PO or IV]

ICU Patients

- > β-lactam [IV] + macrolide [IV] <u>or</u>
- > β -lactam [IV] + quinolone [IV]

ICU Patients with β -lactam Allergy

- ➤ Quinolone + clindamycin [IV] or
- ➤ Quinolone + vancomycin [IV]

References:

- Bartlett JG, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clinical Infectious Diseases. 2000;31:347-382.
- Fine MJ, et al. Validation of pneumonia prognosis index using the Medis Group Comparative Hospital Database. Am J Med. 1993;94:153.
- www.Nationalpneumonia.org/Quality_Indicators/Quality_Indicators.html



INFLUENZA + PNEUMOCOCCAL VACCINATION GUIDELINES

Indications

- 50 years or older for influenza;
 65 years or older for pneumococcal
- Age 2-64 and considered "high risk" due to any of the following:

Chronic disease conditions such as CHF, cardiomyopathy, COPD, emphysema (but not asthma), diabetes, liver disease, renal failure, or use of long term systemic steroids

Compromised immunity conditions (e.g. leukemia, lymphoma, multiple myeloma)

- Note: vaccines may be administered concurrently in different arms
- Contraindications:
 Pneumococcal Vaccine (Vaccine Time: Year-Round)
- Vaccinated prior to admission and revaccination not indicated (see below)
- Currently undergoing chemotherapy or radiation therapy
- · History of idiopathic thrombocytopenic purpura
- Patient refusal
- Contraindications: Influenza Vaccine (Vaccine Time: September–January)
- · Previous immunization this flu season

- Allergy to eggs or to thimerosol (preservative in contact lens solution)
- Severe reaction to previous influenza vaccination (e.g., anaphylaxis)
- · History of idiopathic thrombocytopenic purpura
- Fever over 101° F
- Patient refusal

The following are NOT contraindications to influenza or pneumococcal vaccination:

- Pneumococcal pneumonia during this admission
- Low grade fever (<101°F)
- Surgical procedures
- Colds, rhinitis, UTIs
- Unknown vaccination status

Revaccination: Pneumococcal Vaccine

Recommended if patient was vaccinated 5 or more years ago *and*:

- was less than 65 years when first vaccinated, or
- is at highest risk for pneumococcal infection (asplenic or immunocompromised), or
- is likely to have a rapid decline in pneumococcal antibody rate.

References:

- Centers for Disease Control. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices. MMWR. 1997;46(RR-8).
- Centers for Disease Control. Prevention & control of influenza: recommendations of the Advisory Committee on Immunization Practices. MMWR. 2000;49(RR-3).